Literature DB >> 18615180

Current experimental therapy for Alzheimer's disease.

Sheng Chen1, Xiao-Jie Zhang, Liang Li, Wei-Dong Le.   

Abstract

In the past decade, enormous efforts have been devoted to understand the genetics and molecular pathogenesis of Alzheimer's disease (AD), which has been transferred into extensive experimental approaches aimed at reversing disease progression. The trend in future AD therapy has been shifted from traditional anti-acetylcholinesterase treatment to multiple mechanisms-based therapy targeting amyloid plaques formation and amyloid peptides (Abeta)-mediated cytotoxicity, and neurofibrillary tangles generation. This review will cover current experimental studies with the focus on secretases-based drug development, immunotherapy, and anti-neurofibrillary tangles intervention. The outcome of these on-going studies may provide high hope that AD can be cured in the future.

Entities:  

Keywords:  Alzheimer’s disease; Experimental approach; amyloid plaque; gene therapy; immunotherapy; neurofibrillary tangles; secretase; small interfering molecule

Year:  2007        PMID: 18615180      PMCID: PMC2435347          DOI: 10.2174/157015907780866901

Source DB:  PubMed          Journal:  Curr Neuropharmacol        ISSN: 1570-159X            Impact factor:   7.363


  96 in total

1.  Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.

Authors:  F Bard; C Cannon; R Barbour; R L Burke; D Games; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; I Lieberburg; R Motter; M Nguyen; F Soriano; N Vasquez; K Weiss; B Welch; P Seubert; D Schenk; T Yednock
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

2.  Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.

Authors:  H L Weiner; C A Lemere; R Maron; E T Spooner; T J Grenfell; C Mori; S Issazadeh; W W Hancock; D J Selkoe
Journal:  Ann Neurol       Date:  2000-10       Impact factor: 10.422

3.  Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor.

Authors:  L Hong; G Koelsch; X Lin; S Wu; S Terzyan; A K Ghosh; X C Zhang; J Tang
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

4.  Death in the balance: alternative participation of the caspase-2 and -9 pathways in neuronal death induced by nerve growth factor deprivation.

Authors:  C M Troy; S A Rabacchi; J B Hohl; J M Angelastro; L A Greene; M L Shelanski
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

5.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

Authors:  R B DeMattos; K R Bales; D J Cummins; J C Dodart; S M Paul; D M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

6.  Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques.

Authors:  A Mukherjee; E Song; M Kihiko-Ehmann; J P Goodman; J S Pyrek; S Estus; L B Hersh
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

7.  Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice.

Authors:  E M Sigurdsson; H Scholtzova; P D Mehta; B Frangione; T Wisniewski
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

8.  Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Authors:  D Schenk; R Barbour; W Dunn; G Gordon; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; Z Liao; I Lieberburg; R Motter; L Mutter; F Soriano; G Shopp; N Vasquez; C Vandevert; S Walker; M Wogulis; T Yednock; D Games; P Seubert
Journal:  Nature       Date:  1999-07-08       Impact factor: 49.962

9.  Stereotaxic injection of IgG from patients with Alzheimer disease initiates injury of cholinergic neurons of the basal forebrain.

Authors:  J I Engelhardt; W D Le; L Siklós; I Obál; K Boda; S H Appel
Journal:  Arch Neurol       Date:  2000-05

10.  New protease inhibitors prevent gamma-secretase-mediated production of Abeta40/42 without affecting Notch cleavage.

Authors:  A Petit; F Bihel; C Alvès da Costa; O Pourquié; F Checler; J L Kraus
Journal:  Nat Cell Biol       Date:  2001-05       Impact factor: 28.824

View more
  3 in total

1.  Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors.

Authors:  Sawsan Abuhamdah; Maha Habash; Mutasem O Taha
Journal:  J Comput Aided Mol Des       Date:  2013-12-12       Impact factor: 3.686

2.  Update on the pharmacological treatment of Alzheimer's disease.

Authors:  Fadi Massoud; Serge Gauthier
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

3.  Preservation of dendritic spine morphology and postsynaptic signaling markers after treatment with solid lipid curcumin particles in the 5xFAD mouse model of Alzheimer's amyloidosis.

Authors:  Panchanan Maiti; Zackary Bowers; Ali Bourcier-Schultz; Jarod Morse; Gary L Dunbar
Journal:  Alzheimers Res Ther       Date:  2021-02-08       Impact factor: 8.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.